{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:31:30Z","timestamp":1790685090371,"version":"4.1.0"},"reference-count":108,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2018,12,25]],"date-time":"2018-12-25T00:00:00Z","timestamp":1545696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Onychomycosis is a fungal nail infection caused by dermatophytes, nondermatophyte molds, and yeasts. This difficult\u2010to\u2010treat chronic infection has a tendency to relapse despite treatment. This paper aims to offer a global perspective on onychomycosis management from expert physicians from around the world. Overall, the majority of experts surveyed used systemic, topical, and combination treatments approved in their countries and monitored patients based on the product insert or government recommendations. Although the basics of treating onychomycosis were similar between countries, slight differences in onychomycosis management between countries were found. These differences were mainly due to different approaches to adjunctive therapy, rating the severity of disease and use of prophylaxis treatment. A global perspective on the treatment of onychomycosis provides a framework of success for the committed clinician with appreciation of how onychomycosis is managed worldwide.<\/jats:p>","DOI":"10.1111\/ijd.14346","type":"journal-article","created":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T05:05:04Z","timestamp":1545800704000},"page":"1118-1129","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Global perspectives for the management of onychomycosis"],"prefix":"10.1111","volume":"58","author":[{"given":"Aditya K.","family":"Gupta","sequence":"first","affiliation":[{"name":"Mediprobe Research Incorporated London Canada"},{"name":"Division of Dermatology Department of Medicine University of Toronto Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel R.","family":"Mays","sequence":"additional","affiliation":[{"name":"Mediprobe Research Incorporated London Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah G.","family":"Versteeg","sequence":"additional","affiliation":[{"name":"Mediprobe Research Incorporated London Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Maria","family":"Piraccini","sequence":"additional","affiliation":[{"name":"Division of Dermatology Department of Experimental, Diagnostic and Specialty Medicine University of Bologna Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Takwale","sequence":"additional","affiliation":[{"name":"Gloucestershire Royal Hospital Gloucester United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avner","family":"Shemer","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine Tel\u2010Aviv University Tel\u2010Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meir","family":"Babaev","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences Ben\u2010Gurion University of the Negev Beer\u2010Sheva Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6022-5146","authenticated-orcid":false,"given":"Chander","family":"Grover","sequence":"additional","affiliation":[{"name":"Division of Dermatology and STD University College of Medical Sciences and GTB Hospital Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilton G.","family":"Di Chiacchio","sequence":"additional","affiliation":[{"name":"Dermatology Clinic Hospital do Servidor P\u00fablico Municipal de S\u00e3o Paulo S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo R. O.","family":"Taborda","sequence":"additional","affiliation":[{"name":"Division of Dermatology Faculdade de Medicina do ABC Santo Andr\u00e9 Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria B. A.","family":"Taborda","sequence":"additional","affiliation":[{"name":"Cosmetic Dermatology and Laser Center (Delcentro) Bauru S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil H.","family":"Shear","sequence":"additional","affiliation":[{"name":"Division of Dermatology Department of Medicine University of Toronto Toronto Canada"},{"name":"Division of Dermatology Sunnybrook Health Sciences Centre Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Piguet","sequence":"additional","affiliation":[{"name":"Division of Dermatology Department of Medicine University of Toronto Toronto Canada"},{"name":"Division of Dermatology Women's College Hospital Toronto Canada"},{"name":"Division of Infection and Immunity Cardiff University School of Medicine Cardiff United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Tosti","sequence":"additional","affiliation":[{"name":"Fredric Brandt Endowed Professor of Dermatology University of Miami Miami FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,12,25]]},"reference":[{"issue":"11","key":"e_1_2_14_2_1","first-page":"762","article-title":"Onychomycosis: current trends in diagnosis and treatment","volume":"88","author":"Westerberg DP","year":"2013","journal-title":"Am Fam Physician"},{"issue":"7","key":"e_1_2_14_3_1","first-page":"s96","article-title":"Onchomycosis: an overview","volume":"12","author":"Elewski BE","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12323"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12873"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)80142-3"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.2310\/7750.2014.14090"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.14.76"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12537"},{"issue":"3","key":"e_1_2_14_10_1","first-page":"315","article-title":"Epidemiology of dermatophytoses in Crete, Greece between 2004 and 2010","volume":"147","author":"Maraki S","year":"2012","journal-title":"G Ital Dermatol Venereol"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mycmed.2016.08.009"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-016-0014-7"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12448"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.12989"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.12986"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13677"},{"issue":"5","key":"e_1_2_14_17_1","first-page":"379","article-title":"The prevalence and management of onychomycosis in diabetic patients","volume":"10","author":"Gupta AK","year":"2000","journal-title":"Eur J Dermatol"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2013.08.005"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.11.3.415"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1997.6771624.x"},{"issue":"3","key":"e_1_2_14_21_1","first-page":"320","article-title":"The incidence of onychomycosis infection among patients referred to hospitals in Kermanshah province, Western Iran","volume":"42","author":"Mikaeili A","year":"2013","journal-title":"Iran J Public Health"},{"issue":"2","key":"e_1_2_14_22_1","first-page":"250","article-title":"The prevalence of fungi in fingernail onychomycosis","volume":"7","author":"Gelotar P","year":"2013","journal-title":"J Clin Diagn Res"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-013-1331-2"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8635(03)00035-4"},{"key":"e_1_2_14_25_1","first-page":"17","article-title":"Meta\u2010analysis of the utility of culture, biopsy, and direct KOH examination for the diagnosis of onychomycosis","volume":"22","author":"Velasquez\u2010Agudelo V","year":"2017","journal-title":"BMC Infect Dis"},{"key":"e_1_2_14_26_1","doi-asserted-by":"crossref","first-page":"764843","DOI":"10.1155\/2010\/764843","article-title":"The sensitivity and specificity of potassium hydroxide smear and fungal culture relative to clinical assessment in the evaluation of tinea pedis: a pooled analysis","author":"Levitt JO","year":"2010","journal-title":"Dermatol Res Pract"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1067\/S0190-9622(03)01480-4"},{"key":"e_1_2_14_28_1","first-page":"120347541773346","article-title":"Confirmatory testing prior to initiating onychomycosis therapy is cost\u2010effective","volume":"1","author":"Gupta AK","year":"2017","journal-title":"J Cutan Med Surg"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-016-0248-7"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.7547\/0003-0538-104.4.330"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.158634"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2012.703308"},{"key":"e_1_2_14_33_1","unstructured":"Sporanox.Package insert: SPORANOX! (itraconazole) Capsules. Drugs@FDA: FDA approved drug products [Internet].2012. Available from:www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020083s048s049s050lbl.pdf"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13358"},{"key":"e_1_2_14_35_1","unstructured":"Lamisil.Package Insert: LAMISIL (terbinafine hydrochloride) Tablets 250\u00a0mg Drugs@FDA: FDA Approved Drug Products 2012 [Internet].2012. Available from:www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020539s021lbl.pdf"},{"key":"e_1_2_14_36_1","unstructured":"Diflucan.Package Insert (Fluconazole) Tablets 50 100 150 or 200\u00a0mg [Internet].2011. Drugs@FDA: FDA Approved Drug Products. 2011. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/019949s051lbl.pdf"},{"key":"e_1_2_14_37_1","unstructured":"Sporanox.Package Insert (Itraconazole) Capsules 100\u00a0mg [Internet]. Drugs@FDA: FDA Approved Drug Products.2009. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020083s040s041s044lbl.pdf"},{"issue":"4","key":"e_1_2_14_38_1","first-page":"299","article-title":"Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality","volume":"1","author":"Elewski B","year":"2005","journal-title":"Ther Clin Risk Manag"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1H400"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.10.013"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.1136"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.6836297"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10103-007-0492-4"},{"key":"e_1_2_14_44_1","unstructured":"FDA U.S. Food and Drug Administration.Medical devices and clinical trial design for the treatment or improvement in the appearance of fungally\u2010infected nails [Internet].2016. Available from:https:\/\/www.fda.gov\/downloads\/MedicalDevices\/DeviceRegulationandGuidance\/GuidanceDocuments\/UCM431312.pdf"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14212"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphotobiol.2017.06.010"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13842"},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12042"},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0811"},{"key":"e_1_2_14_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1572-1000(05)00097-9"},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20132180"},{"key":"e_1_2_14_52_1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20142197"},{"issue":"7","key":"e_1_2_14_53_1","first-page":"605","article-title":"Ketoconazole associated hepatotoxicity: a systematic review and meta\u2010 analysis","volume":"26","author":"Yan JY","year":"2013","journal-title":"Biomed Environ Sci BES"},{"key":"e_1_2_14_54_1","unstructured":"LLC VPNA.Jublia (Efinaconazole) Package Insert [Internet]. Bridgewater NJ USA;2014. Available from:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/203567s000lbl.pdf"},{"key":"e_1_2_14_55_1","unstructured":"Anacor Pharmaceuticals Inc.FDA approves Anacor Pharmaceuticals\u2019 KERYDIN\u2122 (tavaborole) topical solution 5% for the treatment of onychomycosis of the toenails [Internet].2014[cited 2014 Nov 24]. Available from:http:\/\/investor.anacor.com\/releasedetail.cfm?ReleaseID=858211"},{"issue":"10","key":"e_1_2_14_56_1","first-page":"1258","article-title":"Comparison of the efficacy of long\u2010pulsed Nd:YAG laser intervention for treatment of onychomycosis of toenails or fingernails","volume":"13","author":"Li Y","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_14_57_1","doi-asserted-by":"publisher","DOI":"10.3314\/mmj.54.333"},{"key":"e_1_2_14_58_1","doi-asserted-by":"publisher","DOI":"10.3109\/14764172.2014.910082"},{"key":"e_1_2_14_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.01.893"},{"key":"e_1_2_14_60_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2016.1151856"},{"key":"e_1_2_14_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.12.002"},{"key":"e_1_2_14_62_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000157"},{"key":"e_1_2_14_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2010.01878.x"},{"key":"e_1_2_14_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13392"},{"key":"e_1_2_14_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.01631.x"},{"key":"e_1_2_14_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2005.01186.x"},{"key":"e_1_2_14_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2012.01769.x"},{"key":"e_1_2_14_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0736-8046.2004.21117.x"},{"key":"e_1_2_14_69_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200016060-00002"},{"key":"e_1_2_14_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.13561"},{"key":"e_1_2_14_71_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.4483"},{"key":"e_1_2_14_72_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.8.15.2465"},{"key":"e_1_2_14_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.10.063"},{"key":"e_1_2_14_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8635(18)30884-2"},{"key":"e_1_2_14_75_1","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.18941"},{"key":"e_1_2_14_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2010.07.008"},{"key":"e_1_2_14_77_1","doi-asserted-by":"publisher","DOI":"10.7547\/87507315-87-12-546"},{"key":"e_1_2_14_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-2478(94)00066-2"},{"key":"e_1_2_14_79_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200910040-00001"},{"key":"e_1_2_14_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.1993.tb00765.x"},{"key":"e_1_2_14_81_1","doi-asserted-by":"publisher","DOI":"10.1186\/1757-1146-4-26"},{"key":"e_1_2_14_82_1","doi-asserted-by":"publisher","DOI":"10.2310\/7750.2006.00054"},{"key":"e_1_2_14_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)90063-8"},{"issue":"6","key":"e_1_2_14_84_1","first-page":"245","article-title":"Improvement of onychomycosis without antifungal therapy after initiation of highly active anti\u2010retroviral therapy (HAART) in an HIV\u2010infected patient","volume":"52","author":"Tachikawa N","year":"1999","journal-title":"Jpn J Infect Dis"},{"key":"e_1_2_14_85_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2011.05346.x"},{"key":"e_1_2_14_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1990.tb04755.x"},{"key":"e_1_2_14_87_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.77577"},{"key":"e_1_2_14_88_1","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.37057"},{"issue":"4","key":"e_1_2_14_89_1","first-page":"213","article-title":"Clinical variations in dermatophytosis in HIV infected patients","volume":"68","author":"Kaviarasan PK","year":"2002","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"e_1_2_14_90_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1439-0507.1999.00405.x"},{"key":"e_1_2_14_91_1","doi-asserted-by":"publisher","DOI":"10.1080\/000155598433566"},{"key":"e_1_2_14_92_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1997.tb03789.x"},{"key":"e_1_2_14_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(92)70163-A"},{"issue":"1","key":"e_1_2_14_94_1","first-page":"55","article-title":"Candida\u2010related denture stomatitis: a pilot study of the efficacy of an amorolfine antifungal varnish","volume":"18","author":"Milillo L","year":"2005","journal-title":"Int J Prosthodont"},{"issue":"1","key":"e_1_2_14_95_1","first-page":"6","article-title":"Role of oral antifungal agents for the treatment of superficial fungal infections in immunocompromised patients","volume":"68","author":"Millikan LE","year":"2001","journal-title":"Cutis"},{"key":"e_1_2_14_96_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2000.00012.x"},{"key":"e_1_2_14_97_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01591361"},{"key":"e_1_2_14_98_1","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.1994.11741156"},{"key":"e_1_2_14_99_1","first-page":"1","article-title":"Onychodystrophy and its management","volume":"1","author":"Oppel T","year":"2003","journal-title":"Ger Med Sci"},{"key":"e_1_2_14_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(98)70490-6"},{"key":"e_1_2_14_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(98)70492-X"},{"key":"e_1_2_14_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(98)70491-8"},{"issue":"3","key":"e_1_2_14_103_1","first-page":"279","article-title":"Onychomycosis: strategies to minimize recurrence","volume":"15","author":"Gupta AK","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_14_104_1","article-title":"The ocular risks of human nail dust in podiatry","author":"McLarnon N","year":"2000","journal-title":"Glasg Caled Univ"},{"key":"e_1_2_14_105_1","first-page":"111","article-title":"Inhalation of nail dust from onychomycotic toenails. Part II: clinical and serological\u00a0aspects","volume":"75","author":"Abramson C","year":"1985","journal-title":"J Am Podiatr Med Assoc"},{"key":"e_1_2_14_106_1","first-page":"2","article-title":"Human nail dust in chiropdial practice: irritant, allergen, and source of antibodies to Trichophyton rubrum","volume":"104","author":"Davies RR","year":"1984","journal-title":"J R Soc Health"},{"issue":"6","key":"e_1_2_14_107_1","first-page":"746","article-title":"Workplace exposure to bioaerosols in podiatry clinics","volume":"56","author":"Coggins MA","year":"2012","journal-title":"Ann Occup Hyg"},{"key":"e_1_2_14_108_1","unstructured":"Gris\u2010Peg.Package Insert (Griseofulvin Ultramicrosized) Tablets 125\u00a0mg; 250\u00a0mg [Internet]. Drugs@FDA: FDA Approved Drug Products.2016. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/050475s057lbl.pdf"},{"key":"e_1_2_14_109_1","unstructured":"Nizoral.Package Insert (Ketoconazole) Tablets 200\u00a0mg [Internet]. Drugs@FDA: FDA Approved Drug Products.2013. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/018533s040lbl.pdf"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijd.14346","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.14346","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijd.14346","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.14346","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T16:35:55Z","timestamp":1720888555000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.14346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,25]]},"references-count":108,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1111\/ijd.14346"],"URL":"https:\/\/doi.org\/10.1111\/ijd.14346","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,25]]},"assertion":[{"value":"2018-06-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}